Media headlines about Myriad Genetics (NASDAQ:MYGN) have been trending somewhat positive on Wednesday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Myriad Genetics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.4044397451252 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
MYGN has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 15th. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Morgan Stanley raised their price objective on shares of Myriad Genetics from $24.00 to $26.00 and gave the company an “underweight” rating in a research note on Wednesday, November 8th. Deutsche Bank raised their price objective on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, November 8th. Finally, Goldman Sachs Group initiated coverage on shares of Myriad Genetics in a research note on Monday, January 29th. They issued a “sell” rating and a $32.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $31.42.
Shares of Myriad Genetics (NASDAQ MYGN) opened at $32.10 on Wednesday. The company has a quick ratio of 1.81, a current ratio of 2.05 and a debt-to-equity ratio of 0.05. The firm has a market cap of $2,240.00, a price-to-earnings ratio of 17.45, a price-to-earnings-growth ratio of 2.33 and a beta of 0.44. Myriad Genetics has a twelve month low of $17.50 and a twelve month high of $41.57.
Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, February 6th. The company reported $0.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.07. The company had revenue of $194.00 million for the quarter, compared to analyst estimates of $188.72 million. Myriad Genetics had a net margin of 16.67% and a return on equity of 9.59%. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period last year, the business posted $0.26 earnings per share. sell-side analysts anticipate that Myriad Genetics will post 1.15 EPS for the current year.
In other Myriad Genetics news, VP Richard M. Marsh sold 37,654 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $40.25, for a total value of $1,515,573.50. Following the sale, the vice president now directly owns 157,648 shares in the company, valued at $6,345,332. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Walter Phd Gilbert sold 7,500 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $33.19, for a total transaction of $248,925.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 68,033 shares of company stock worth $2,583,197. Company insiders own 6.70% of the company’s stock.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.